Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 16 of 39, showing 5 Applications out of 192 total, starting on record 76, ending on 80

# Protocol No Study Title Investigator(s) & Site(s)

76.

ECCT/24/02/06   INAVO122
    A phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Inavolisib in combination with Phesgo versus placebo in combination with Phesgo as maintenance therapy after first line induction therapy in participants with PIK3CA‐mutated HER2‐positive locally advanced or metastatic breast cancer   
Principal Investigator(s)
1. Dr Sitna Ali
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
View

77.

ECCT/22/01/04   SKYSCRAPER 07
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE CANCERS HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY   
Principal Investigator(s)
1. Fredrick Chite Asirwa
2. Mansoor Saleh
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
View

78.

ECCT/24/06/05   SII-qHPV Vaccine Study
    A Phase-3b, partially double-blind, randomized, multi-country clinical study to evaluate the immunogenicity, safety, and reactogenicity of SIIPL qHPV vaccine (CERVAVAC®) in women living with HIV aged 15-25 years.   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
1. KEMRI-CCR PHRD Thika (Kiambu county)
2. KEMRI - CCR Nairobi (Nairobi City county)
 
View

79.

ECCT/15/12/05   Post-discharge Malaria Chemoprevention(PMC) study
    Malaria Chemoprevention with monthly treatment with dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: A 3-year, multi-centre, parallel-group, two-arm randomised placebo controlled superiority trial   
Principal Investigator(s)
1. Titus Kwambai
2. Simon Kariuki
Site(s) in Kenya
1. Siaya County Referral Hospital (Siaya county)
2. Homa Bay County Referral Hospital (Homa Bay county)
3. Migori County Referral Hospital (Migori county)
4. Busia County Referral Hospital (Busia county)
 
View

80.

ECCT/21/09/04   Recombinant COVID-19 Vaccine
    A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells) for the prevention of COVID-19 in adults aged 18 years and older            
Principal Investigator(s)
1. Sylvester Kimaiyo
Site(s) in Kenya
1. KAVI-Institute of Clinical Research (Nairobi City county)
2. Moi Teaching and Referral Hospital (Uasin Gishu county)
3. Kenya Medical Research Institute, Kilifi (Kilifi county)
 
View